This study is in progress, not accepting new patients
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Head and Neck Squamous Cell Cancer Squamous cell carcinoma Head and neck carcinoma PD1 PD-1 PDL1 PD-L1 Head and Neck Neoplasms Neoplasms, Squamous Cell Carcinoma, Squamous Cell Docetaxel Pembrolizumab Methotrexate Cetuximab Pembroliziumab
Lead Scientist at UCSF
- Alain Algazi
Associate Professor, Medicine. Authored (or co-authored) 63 research publications.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Merck Sharp & Dohme Corp.
- Phase 3
- Study Type
- Last Updated